Diabetic osteopathy: previously disputed but most likely important ailment

Czech version

Authors: Š. Svačina
Authors‘ workplace: III. interní klinika 1. lékařské fakulty UK a VFN Praha, přednosta prof. MUDr. Štěpán Svačina, DrSc., MBA
Published in: Vnitř Lék 2010; 56(7): 736-738
Category: 80th Birthday - Jaroslava Blahoše, MD, DrSc.

Overview

Diabetic osteopathy is usually not mentioned in the list of diabetic complications. This osteopathy is very important in clinical medicine. In the pathogenesis many factors are involved – bone formation, hyperglycaemia, glycosuria, glycation of collagene etc. Clinically important is the high risk of fractures present in diabetic patients. This risk can be positively and negatively modified by antidiabetic drugs. It is important to find some markers for fracture risk in diabetes. Nowadays only bone densitometry can be used with some limitations to quantify this risk.

Key words:
diabetic osteopathy – bone fracture – antidiabetic drugs – risk markers

Sources

1. Vencovský J. Muskuloskeletální projevy u diabetes mellitus. In: Svačina Š et al (eds). Poruchy metabolismu a výživy. Praha: Galén 2010.

2. Sobotka L. Sarkopenie seniorů. In: Svačina Š et al (ed). Poruchy metabolismu a výživy. Praha: Galén 2010.

3. Isidro ML, Ruano B. Bone disease in diabetes. Curr Diabetes Rev 2010; 6: 144–155.

4. Schwartz AV. Diabetes Mellitus: Does it Affect Bone? Calcif Tissue Int 2003; 73: 515–519.

5. Leidig-Bruckner G, Ziegler R. Diabetes mellitus a risk for osteoporosis? Exp Clin Endocrinol Diabetes 2001; 109 (Suppl 2): S493–S514.

6. Raska I Jr, Broulík P. The impact of diabetes mellitus on skeletal health: an established phenomenon with in established causes? Prague Med Rep 2005; 106: 137–148.

7. Amano A, Kawai S. Diabetes and oral osteoporosis. Clin Calcium 2007; 17: 186–191.

8. Lalla E, Lamster IB, Feit M et al. Blockade of RAGE suppresses periodontitis‑associated bone loss in diabetic mice. J Clin Invest 2000; 105: 1117–1124.

9. Won HY, Park JB, Park EY et al. Effect of hyperglycemia on apoptosis of notochordal cells and intervertebral disc degeneration in diabetic rats. J Neurosurg Spine 2009; 11: 741–748.

10. Li H, Jiang LS, Dai LY. High glucose potentiates collagen synthesis and bone morphogenetic protein‑2‑induced early osteoblast gene expression in rat spinal ligament cells. Endocrinology 2010; 151: 63–74.

11. Fantuzzi G, Mazzone TH. Adipose tissue in health and disease. Totowa: Humana Press 2007.

12. Haluzík M, Svačina Š. Metabolické jaderní receptory PPAR. Praha: Grada Publishing 2004.

13. Shockley KR, Lazarenko OP, Czernik PJ et al. PPAR2 nuclear receptor controls multiple regulatory pathways of osteoblast differentiation from marrow mesenchymal stem cells. J Cell Biochem 2009; 106: 232–246.

14. Botushanov NP, Orbetzova MM. Bone mineral density and fracture risk in patients with type 1 and type 2 diabetes mellitus. Folia Med (Plovdiv) 2009; 51: 12–17.

15. Adami S. Bone health in diabetes: considerations for clinical management. Curr Med Res Opin 2009; 25: 1057–1072.

16. Strotmeyer ES, Cauley JA, Schwartz AV et al. Nontraumatic fracture risk with diabetes mellitus and impaired fasting glucose in older white and black adults: the health, aging, and body composition study. Arch Intern Med 2005; 165: 1612–1617.

17. Kahn SE, Zinman B, Lachin JM et al. Rosiglitazone‑associated fractures in type 2 diabetes: an Analysis from A Diabetes Outcome Progression Trial (ADOPT). Diabetes Care 2008; 31: 845–851.

18. Palička V. Léky ovlivňující kostní metabolismus u diabetiků. Vnitř Lék 2009; 55: 368–370.

19. Svačina Š. Diabetes, antidiabetika a kost. Čas Lék čes 2010; 149: 282–284.

20. Gao Y, Li Y, Xue J et al. Effect of the anti‑diabetic drug metformin on bone mass in ovariectomized rats. Eur J Pharmacol 2010; 635: 231–236.

21. Yamada C, Yamada Y, Tsukiyama K et al. The murine glucagon‑like peptide-1 receptor is essential for control of bone resorption. Endocrinology 2008; 149: 574–579.

22. Kimura T, Kuwata T, Ashimine S et al. Targeting of bone-derived insulin‑like growth factor-II by a human neutralizing antibody suppresses the growth of prostate cancer cells in a human bone environment. Clin Cancer Res 2010; 16: 121–129.

23. Matsumura M, Monden T, Nakatani Y et al. Effect of raloxifene on serum lipids for type 2 diabetic menopausal women with or without statin treatment. Med Princ Pract 2010; 19: 68–72.

24. Schulz TJ, Tseng YH. Emerging role of bone morphogenetic proteins in adipogenesis and energy metabolism. Cytokine Growth Factor Rev 2009; 20: 523–531.

25. Hruska KA, Mathew S, Saab G. Bone morphogenetic proteins in vascular calcification. Circ Res 2005; 97: 105–114.